MCNU in the treatment of essential thrombocythemia--a pilot study.

Abstract

The efficacy of a single dose of MCNU 150 mg was evaluated in nine symptomatic patients with essential thrombocythemia (ET). As the platelet counts increased during the following 4 weeks, an extra dose of 100 mg of MCNU was administered to three patients. All patients had thrombotic or hemorrhagic complications. Seven patients responded. The mean platelet count decreased to below 1.0 x 10(12)/l within 5 weeks; it reached its lowest level (0.35 x 10(12)/l) at 6 weeks and became stable at less than 1.0 x 10(12)/l without further therapy for 12 weeks in all patients. Thrombotic and hemorrhagic complications ameliorated within 4 weeks in all patients. Our study indicates that MCNU acts as a platelet-reducing agent in patients with ET.

• Authors: H Murakami, J Tamura, M Sawamura
• Journal: Annals of hematology (Ann Hematol) Vol. 66 Issue 5 Pg. 247-9 (May 1993) ISSN: 0939-5555 [Print] Germany
• PMID: 8507720 (Publication Type: Journal Article)

Chemical References

• Nitrosourea Compounds
• ranimustine

Topics

• Adult
• Aged
• Female
• Humans
• Male
• Middle Aged
• Nitrosourea Compounds (administration & dosage, adverse effects, therapeutic use)
• Pilot Projects
• Platelet Count
• Thrombocythemia, Essential (blood, drug therapy)